Weigao Group Announces Overseas Regulatory Filing for Orthopaedic Subsidiary

Bulletin Express
08/25

Shandong Weigao Group Medical Polymer Company Limited (“Weigao Group”) has released an overseas regulatory announcement in compliance with Rule 13.10B of the Hong Kong Stock Exchange Listing Rules.

The company disclosed that Shandong Weigao Orthopaedic Device Company Limited has published an announcement on the Shanghai Stock Exchange’s website (http://www.sse.com.cn/home/search/?webswd=688161). The Hong Kong filing serves to mirror that disclosure for international investors and ensure alignment with cross-border reporting requirements.

The statement reiterates that Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited assume no responsibility for the contents of the announcement.

Corporate governance details were also provided: the Weigao Group Board currently comprises four Executive Directors (Long Jing, Cong Rinan, Lu Junqiang, Wang Daoming), two Non-executive Directors (Chen Lin, Tang Zhengpeng) and four Independent Non-executive Directors (Li Guohui, Meng Hong, Li Qiang, Sun Heng).

The announcement was authorised by Chairman Long Jing and dated 25 August 2026 in Weihai, Shandong, PRC.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10